Search: WFRF:(Bezard Erwan)
> (2010-2014)
> Iderberg Hanna >
A mGluR5 antagonist...
A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys.
-
- Rylander, Daniella (author)
- Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
-
- Iderberg, Hanna (author)
- Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
-
Li, Qin (author)
-
show more...
-
Dekundy, Andrzej (author)
-
Zhang, Jinlan (author)
-
Li, Hao (author)
-
Baishen, Ren (author)
-
Danysz, Wojciech (author)
-
Bezard, Erwan (author)
-
- Cenci Nilsson, Angela (author)
- Lund University,Lunds universitet,Basala gangliernas patofysiologi,Forskargrupper vid Lunds universitet,Basal Ganglia Pathophysiology,Lund University Research Groups
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2010
- 2010
- English.
-
In: Neurobiology of Disease. - : Elsevier BV. - 0969-9961. ; 39, s. 352-361
- Related links:
-
http://www.ncbi.nlm....
-
show more...
-
http://dx.doi.org/10...
-
https://lup.lub.lu.s...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- L-DOPA remains the gold-standard treatment for Parkinson's disease but causes motor fluctuations and dyskinesia. Metabotropic glutamate receptor type 5 (mGluR5) has been proposed as a target for antidyskinetic therapies. Here, we evaluate the effects of fenobam, a noncompetitive mGluR5 antagonist already tested in humans, using rodent and nonhuman primate models of L-DOPA-induced dyskinesia. In both animal models, acute administration of fenobam attenuated the L-DOPA-induced abnormal involuntary movements (50-70% reduction at the doses of 30mg/kg in rats and 10mg/kg in monkeys). The effect consisted in a reduction of peak-dose dyskinesia, whereas the end-dose phase was not affected. Chronic administration of fenobam to previously drug-naïve animals (de novo treatment) attenuated the development of peak-dose dyskinesia without compromising the anti-parkinsonian effect of L-DOPA. In addition, fenobam prolonged the motor stimulant effect of L-DOPA. We conclude that fenobam acts similarly in rat and primate models of L-DOPA-induced dyskinesia and that it represents a good candidate for antidyskinetic treatment in Parkinson's disease.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
Publication and Content Type
- art (subject category)
- ref (subject category)
Find in a library
To the university's database
- By the author/editor
-
Rylander, Daniel ...
-
Iderberg, Hanna
-
Li, Qin
-
Dekundy, Andrzej
-
Zhang, Jinlan
-
Li, Hao
-
show more...
-
Baishen, Ren
-
Danysz, Wojciech
-
Bezard, Erwan
-
Cenci Nilsson, A ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
- Articles in the publication
-
Neurobiology of ...
- By the university
-
Lund University